JP2016514719A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514719A5 JP2016514719A5 JP2016503669A JP2016503669A JP2016514719A5 JP 2016514719 A5 JP2016514719 A5 JP 2016514719A5 JP 2016503669 A JP2016503669 A JP 2016503669A JP 2016503669 A JP2016503669 A JP 2016503669A JP 2016514719 A5 JP2016514719 A5 JP 2016514719A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- independently
- alkylene
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 39
- 239000001257 hydrogen Substances 0.000 claims 38
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000002431 hydrogen Chemical class 0.000 claims 18
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 16
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000001204 N-oxides Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 239000011780 sodium chloride Substances 0.000 claims 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- -1 phenyl ring halogen Chemical class 0.000 claims 10
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000005842 heteroatoms Chemical group 0.000 claims 4
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 206010027476 Metastasis Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 210000004369 Blood Anatomy 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 230000003463 hyperproliferative Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 claims 1
- 125000004515 1,2,4-thiadiazol-3-yl group Chemical group S1N=C(N=C1)* 0.000 claims 1
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- AQYSYJUIMQTRMV-UHFFFAOYSA-N Hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000000973 chemotherapeutic Effects 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000003145 oxazol-4-yl group Chemical group O1C=NC(=C1)* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- 125000004943 pyrimidin-6-yl group Chemical group N1=CN=CC=C1* 0.000 claims 1
- 0 CC(*)(C=C1)C=Cc2c1c(-c1ncc(*)c(NC3=*C(C)(*)C=NC=C3)n1)n[n]2 Chemical compound CC(*)(C=C1)C=Cc2c1c(-c1ncc(*)c(NC3=*C(C)(*)C=NC=C3)n1)n[n]2 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13160444.9 | 2013-03-21 | ||
| EP13160444 | 2013-03-21 | ||
| PCT/EP2014/055658 WO2014147204A1 (en) | 2013-03-21 | 2014-03-20 | Heteroaryl substituted indazoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016514719A JP2016514719A (ja) | 2016-05-23 |
| JP2016514719A5 true JP2016514719A5 (pt-PT) | 2017-04-20 |
Family
ID=47900959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503669A Pending JP2016514719A (ja) | 2013-03-21 | 2014-03-20 | ヘテロアリール置換インダゾール |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20160046604A1 (pt-PT) |
| EP (1) | EP2976335A1 (pt-PT) |
| JP (1) | JP2016514719A (pt-PT) |
| CN (1) | CN105164116A (pt-PT) |
| CA (1) | CA2907594A1 (pt-PT) |
| HK (1) | HK1223350A1 (pt-PT) |
| WO (1) | WO2014147204A1 (pt-PT) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| CA2859779A1 (en) | 2011-12-21 | 2013-06-27 | Bayer Intellectual Property Gmbh | Substituted benzylpyrazoles |
| EP2976334A1 (en) * | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Diaminoheteroaryl substituted indazoles |
| CA2907592A1 (en) * | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| CN105408324A (zh) | 2013-06-21 | 2016-03-16 | 拜耳制药股份公司 | 取代的苄基吡唑 |
| CN105452237A (zh) | 2013-06-21 | 2016-03-30 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| EP3063138A1 (en) | 2013-10-30 | 2016-09-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| US10428044B2 (en) | 2014-06-17 | 2019-10-01 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones |
| AP2017009803A0 (en) | 2014-09-19 | 2017-03-31 | Bayer Pharma AG | Benzyl substituted indazoles as bub1 inhibitors |
| EP3194378A1 (en) * | 2014-09-19 | 2017-07-26 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles |
| CA2974853C (en) | 2015-01-28 | 2023-02-21 | Bayer Pharma Aktiengesellschaft | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CA2989469A1 (en) | 2015-06-17 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| JP2019504826A (ja) * | 2015-12-16 | 2019-02-21 | バイエル ファーマ アクチエンゲゼルシャフト | ヘテロ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類 |
| WO2017148995A1 (en) | 2016-03-04 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity |
| WO2017157992A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders |
| WO2017157991A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| JP7090639B2 (ja) | 2017-04-11 | 2022-06-24 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | フッ素置換されたインダゾール化合物及びその使用 |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
| CA3196712A1 (en) | 2020-09-23 | 2022-03-31 | Scorpion Therapeutics, Inc. | Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer |
| WO2022072634A1 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Bicyclic compounds for use in the treatment cancer |
| WO2022072645A2 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| KR20230107419A (ko) | 2020-10-09 | 2023-07-14 | 스코르피온 테라퓨틱스, 인코퍼레이티드 | 암 치료 방법 |
| WO2022094271A1 (en) | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| WO2022197913A1 (en) | 2021-03-18 | 2022-09-22 | Scorpion Therapeutics, Inc. | Bicyclic derivatives which can be used to treat cancer |
| WO2023173083A1 (en) | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
| EP4293019A1 (en) * | 2022-06-13 | 2023-12-20 | Netherlands Translational Research Center Holding B.V. | 4-substituted (1h-benzo[d]imidazol-2-yl)-1h-pyrazoles as bub1 inhibitors useful for treating cancers |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007065010A2 (en) * | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Anti-angiogenesis compounds |
| DE102006027156A1 (de) * | 2006-06-08 | 2007-12-13 | Bayer Schering Pharma Ag | Sulfimide als Proteinkinaseinhibitoren |
| JP2010111624A (ja) * | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| UA111754C2 (uk) * | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| CN103947300B (zh) * | 2011-11-28 | 2016-03-09 | 皇家飞利浦有限公司 | 照明设备以及操作放电灯的方法 |
| CA2859779A1 (en) * | 2011-12-21 | 2013-06-27 | Bayer Intellectual Property Gmbh | Substituted benzylpyrazoles |
| DE102012200352A1 (de) * | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
| JP2015520143A (ja) * | 2012-05-11 | 2015-07-16 | バイエル ファーマ アクチエンゲゼルシャフト | 癌を治療するためのｂｕｂ１阻害薬としての置換されているシクロアルケノピラゾール類 |
| CN104936956A (zh) * | 2013-01-30 | 2015-09-23 | 拜耳制药股份公司 | 氨基取代的异噻唑 |
| CA2907592A1 (en) * | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| EP2976334A1 (en) * | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Diaminoheteroaryl substituted indazoles |
| CN105452237A (zh) * | 2013-06-21 | 2016-03-30 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| CA2916097A1 (en) * | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| EP3010911A1 (en) * | 2013-06-21 | 2016-04-27 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| CN105408324A (zh) * | 2013-06-21 | 2016-03-16 | 拜耳制药股份公司 | 取代的苄基吡唑 |
| WO2014202586A1 (en) * | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Diaminoheteroaryl substituted pyrazoles |
-
2014
- 2014-03-20 CA CA2907594A patent/CA2907594A1/en not_active Abandoned
- 2014-03-20 CN CN201480025220.8A patent/CN105164116A/zh active Pending
- 2014-03-20 US US14/778,733 patent/US20160046604A1/en not_active Abandoned
- 2014-03-20 WO PCT/EP2014/055658 patent/WO2014147204A1/en active Application Filing
- 2014-03-20 EP EP14711968.9A patent/EP2976335A1/en not_active Withdrawn
- 2014-03-20 JP JP2016503669A patent/JP2016514719A/ja active Pending
-
2016
- 2016-06-10 HK HK16106656.4A patent/HK1223350A1/zh unknown
-
2017
- 2017-03-10 US US15/456,239 patent/US20170275268A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016514719A5 (pt-PT) | ||
| JP2016514718A5 (pt-PT) | ||
| EP3481815B1 (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
| KR102007056B1 (ko) | 과증식성 질환 치료시 Bub1 키나제 저해제로 사용하기 위한 치환된 벤질인다졸 | |
| JP2016522232A5 (pt-PT) | ||
| JP2016525075A5 (pt-PT) | ||
| ES2829270T3 (es) | Derivados de sulfonamida aromáticos | |
| JP2019532084A5 (pt-PT) | ||
| JP2015518899A5 (pt-PT) | ||
| JP2016525076A5 (pt-PT) | ||
| JP5864589B2 (ja) | 細菌トポイソメラーゼｉｉ阻害性２−エチルカルバモイルアミノ−１，３−ベンゾチアゾール−５−イル類 | |
| JP2019094350A (ja) | 抗癌活性及び抗増殖活性を呈する２−アミノピリミジン−６−オン及び類似体 | |
| JP2016525135A5 (pt-PT) | ||
| JP2017526726A5 (pt-PT) | ||
| JP2018519343A5 (pt-PT) | ||
| JP2015537017A5 (pt-PT) | ||
| JP2016522231A5 (pt-PT) | ||
| JP2017538721A5 (pt-PT) | ||
| JP2014513110A5 (pt-PT) | ||
| JP2016516043A5 (pt-PT) | ||
| JP2015514808A5 (pt-PT) | ||
| JP2016526540A5 (pt-PT) | ||
| JP2016517417A5 (pt-PT) | ||
| JP2020507582A5 (pt-PT) | ||
| JP2016514717A5 (pt-PT) |